{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T03:14:18Z","timestamp":1784258058259,"version":"3.55.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T00:00:00Z","timestamp":1683590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T00:00:00Z","timestamp":1683590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-023-03376-w","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:08:18Z","timestamp":1683763698000},"page":"409-418","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Parathyroid carcinoma: molecular therapeutic targets"],"prefix":"10.1007","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3678-4922","authenticated-orcid":false,"given":"Francesca","family":"Marini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8576-9606","authenticated-orcid":false,"given":"Francesca","family":"Giusti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8376-7404","authenticated-orcid":false,"given":"Gaia","family":"Palmini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2308-2139","authenticated-orcid":false,"given":"Cinzia","family":"Aurilia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2973-6030","authenticated-orcid":false,"given":"Simone","family":"Donati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8741-0592","authenticated-orcid":false,"given":"Maria Luisa","family":"Brandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,9]]},"reference":[{"key":"3376_CR1","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.humpath.2022.05.014","volume":"127","author":"Y Gao","year":"2022","unstructured":"Y. Gao, P. Wang, J. Lu, B. Pan, D. Guo, Z. Zhang, A. Wang, M. Zhang, J. Sun, W. Wang, Z. Liang, Diagnostic significance of parafibromin expression in parathyroid carcinoma. Hum. Pathol. 127, 28\u201338 (2022). https:\/\/doi.org\/10.1016\/j.humpath.2022.05.014","journal-title":"Hum. Pathol."},{"key":"3376_CR2","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1016\/j.ejso.2021.06.026","volume":"47","author":"S Leonard-Murali","year":"2021","unstructured":"S. Leonard-Murali, T. Ivanics, D.S. Kwon, X. Han, C.P. Steffes, R. Shah, Local resection versus radical surgery for parathyroid carcinoma: a national cancer database analysis. Eur. J. Surg. Oncol. 47, 2768\u20132773 (2021). https:\/\/doi.org\/10.1016\/j.ejso.2021.06.026","journal-title":"Eur. J. Surg. Oncol."},{"key":"3376_CR3","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1245\/s10434-018-6559-6","volume":"25","author":"WM Lo","year":"2018","unstructured":"W.M. Lo, M.L. Good, N. Nilubol, N.D. Perrier, D.T. Patel, Tumor size and presence of metastatic disease at diagnosis are associated with disease-specific survival in parathyroid carcinoma. Ann. Surg. Oncol. 25, 2535\u20132540 (2018). https:\/\/doi.org\/10.1245\/s10434-018-6559-6","journal-title":"Ann. Surg. Oncol."},{"issue":"1","key":"3376_CR4","doi-asserted-by":"publisher","first-page":"IJE06","DOI":"10.2217\/ije-2017-0011","volume":"5","author":"LK Long","year":"2018","unstructured":"L.K. Long, R.S. Sippel, Current and future treatment for parathyroid carcinoma. Int. J. Endo. Oncol. 5(1), IJE06 (2018). https:\/\/doi.org\/10.2217\/ije-2017-0011","journal-title":"Int. J. Endo. Oncol."},{"issue":"3","key":"3376_CR5","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1210\/js.2018-00043","volume":"3","author":"CN Clarke","year":"2018","unstructured":"C.N. Clarke, P. Katsonis, T.K. Hsu, A.M. Koire, A. Silva-Figueroa, I. Christakis, M.D. Williams, M. Kutahyalioglu, L. Kwatampora, Y. Xi, J.E. Lee, E.S. Koptez, N.L. Busaidy, N.D. Perrier, O. Lichtarge, Comprehensive genomic characterization of parathyroid cancer identifies novel candidate driver mutations and core pathways. J. Endocr. Soc. 3(3), 544\u2013559 (2018). https:\/\/doi.org\/10.1210\/js.2018-00043","journal-title":"J. Endocr. Soc."},{"key":"3376_CR6","doi-asserted-by":"publisher","first-page":"834362","DOI":"10.3389\/fendo.2022.834362","volume":"13","author":"F Marini","year":"2022","unstructured":"F. Marini, F. Giusti, G. Palmini, G. Perigli, R. Santoro, M.L. Brandi, Genetics and epigenetics of parathyroid carcinoma. Front. Endocrinol. 13, 834362 (2022). https:\/\/doi.org\/10.3389\/fendo.2022.834362","journal-title":"Front. Endocrinol."},{"issue":"8","key":"3376_CR7","doi-asserted-by":"publisher","first-page":"T53","DOI":"10.1530\/ERC-20-0018","volume":"27","author":"ND Perrier","year":"2020","unstructured":"N.D. Perrier, A. Arnold, J. Costa-Guda, N.L. Busaidy, H. Nguyen, H.H. Chuang, M.L. Brandi, Hereditary endocrine tumours: current state-of-the-art and research opportunities: new and future perspectives for parathyroid carcinoma. Endocr. Relat. Cancer 27(8), T53\u2013T63 (2020). https:\/\/doi.org\/10.1530\/ERC-20-0018","journal-title":"Endocr. Relat. Cancer"},{"issue":"13","key":"3376_CR8","doi-asserted-by":"publisher","first-page":"6981","DOI":"10.3390\/ijms23136981","volume":"23","author":"R Uljanovs","year":"2022","unstructured":"R. Uljanovs, S. Sinkarevs, B. Strumfs, L. Vidusa, K. Merkurjeva, I. Strumfa, Immunohistochemical profile of parathyroid tumours: a comprehensive review. Int. J. Mol. Sci. 23(13), 6981 (2022). https:\/\/doi.org\/10.3390\/ijms23136981","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"3376_CR9","doi-asserted-by":"publisher","first-page":"e92061","DOI":"10.1172\/jci.insight.92061","volume":"2","author":"C Pandya","year":"2017","unstructured":"C. Pandya, A.V. Uzilov, J. Bellizzi, C.Y. Lau, A.S. Moe, M. Strahl, W. Hamou, L.C. Newman, M.Y. Fink, Y. Antipin, W. Yu, M. Stevenson, B.M. Cavaco, B.T. The, R.V. Thakker, H. Morreau, E.E. Schadt, R. Sebra, S.D. Li, A. Arnold, R. Chen, Genomic profiling reveals mutational landscape in parathyroid carcinomas. Jci. Insight 2(6), e92061 (2017). https:\/\/doi.org\/10.1172\/jci.insight.92061","journal-title":"Jci. Insight"},{"issue":"7","key":"3376_CR10","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1007\/s00268-014-2455-9","volume":"38","author":"L Zhao","year":"2014","unstructured":"L. Zhao, L.H. Sun, D.M. Liu, X.Y. He, B. Tao, G. Ning, J.M. Liu, H.Y. Zhao, Copy number variation in CCND1 gene is implicated in the pathogenesis of sporadic parathyroid carcinoma. World J. Surg. 38(7), 1730\u20131737 (2014). https:\/\/doi.org\/10.1007\/s00268-014-2455-9","journal-title":"World J. Surg."},{"key":"3376_CR11","doi-asserted-by":"publisher","first-page":"853171","DOI":"10.3389\/fendo.2022.853171","volume":"13","author":"HS Park","year":"2022","unstructured":"H.S. Park, Y.H. Lee, N. Hong, D. Won, Y. Rhee, Germline mutations related to primary hyperparathyroidism identified by next-generation sequencing. Front. Endocrinol. 13, 853171 (2022). https:\/\/doi.org\/10.3389\/fendo.2022.853171","journal-title":"Front. Endocrinol."},{"issue":"9","key":"3376_CR12","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1002\/ijc.33166","volume":"147","author":"Y Hu","year":"2020","unstructured":"Y. Hu, X. Zhang, O. Wang, Y. Bi, X. Xing, M. Cui, M. Wang, W. Tao, Q. Liao, Y. Zhao, The genomic profile of parathyroid carcinoma based on whole-genome sequencing. Int. J. Cancer 147(9), 2446\u20132457 (2020). https:\/\/doi.org\/10.1002\/ijc.33166","journal-title":"Int. J. Cancer"},{"issue":"6","key":"3376_CR13","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1634\/theoncologist.2018-0334","volume":"24","author":"H Kang","year":"2019","unstructured":"H. Kang, D. Pettinga, A.D. Schubert, P.W. Ladenson, D.W. Ball, J.H. Chung, A.B. Schrock, R. Madison, G.M. Frampton, P.J. Stephens, J.S. Ross, V.A. Miller, S.M. Ali, Genomic profiling of parathyroid carcinoma reveals genomic alterations suggesting benefit from therapy. Oncologist 24(6), 791\u2013797 (2019). https:\/\/doi.org\/10.1634\/theoncologist.2018-0334","journal-title":"Oncologist"},{"issue":"8","key":"3376_CR14","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1007\/s00432-019-02945-9","volume":"145","author":"M Kutahyalioglu","year":"2019","unstructured":"M. Kutahyalioglu, H.T. Nguyen, L. Kwatampora, C. Clarke, A. Silva, E. Ibrahim, S.G. Waguespack, M.E. Cabanillas, C. Jimenez, M.I. Hu, S.I. Sherman, S. Kopetz, R. Broaddus, R. Dadu, K. Wanland, M. Williams, M. Zafereo, N. Perrier, N.L. Busaidy, Genetic profiling as a clinical tool in advanced parathyroid carcinoma. J. Cancer Res. Clin. Oncol. 145(8), 1977\u20131986 (2019)","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"3376_CR15","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s00432-019-02945-9","volume":"6","author":"HL Robbins","year":"2015","unstructured":"H.L. Robbins, A. Hague, The PI3K\/Akt pathway in tumors of endocrine tissues. Front. Endocrinol. 6, 188 (2015). https:\/\/doi.org\/10.1007\/s00432-019-02945-9","journal-title":"Front. Endocrinol."},{"key":"3376_CR16","doi-asserted-by":"publisher","first-page":"745","DOI":"10.3390\/endocrines3040061","volume":"3","author":"SH Kong","year":"2022","unstructured":"S.H. Kong, Updates of genomics and proteomics of parathyroid carcinoma. Endocrines 3, 745\u2013752 (2022). https:\/\/doi.org\/10.3390\/endocrines3040061","journal-title":"Endocrines"},{"issue":"6","key":"3376_CR17","doi-asserted-by":"publisher","first-page":"e10360","DOI":"10.1002\/jbm4.10360","volume":"4","author":"A Riccardi","year":"2020","unstructured":"A. Riccardi, C. Lemos, R. Ramos, J. Bellizzi, K. Parham, T.C. Brown, R. Korah, T. Carling, J. Costa-Guda, A. Arnold, PIK3CA mutational analysis of parathyroid adenomas. JBMR 4(6), e10360 (2020). https:\/\/doi.org\/10.1002\/jbm4.10360","journal-title":"JBMR"},{"key":"3376_CR18","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/onc.2016.304","volume":"36","author":"T Zhan","year":"2017","unstructured":"T. Zhan, N. Rindtorff, M. Boutros, Wnt signaling in cancer. Oncogene 36, 1461\u20131473 (2017). https:\/\/doi.org\/10.1038\/onc.2016.304","journal-title":"Oncogene"},{"key":"3376_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-9-294","volume":"9","author":"J Svedlund","year":"2010","unstructured":"J. Svedlund, M. Aur\u00e9n, M. Sundstr\u00f6m, H. Dralle, G. Akerstr\u00f6m, P. Bj\u00f6rklund, G. Westin, Aberrant WNT\/\u03b2-catenin signaling in parathyroid carcinoma. Mol. Cancer 9, 294 (2010). https:\/\/doi.org\/10.1186\/1476-4598-9-294","journal-title":"Mol. Cancer"},{"issue":"2","key":"3376_CR20","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1530\/ERC-13-0497","volume":"21","author":"J Svedlund","year":"2014","unstructured":"J. Svedlund, E. Barazeghi, P. St\u00e5lberg, P. Hellman, G. \u00c5kerstr\u00f6m, P. Bj\u00f6rklund, G. Westin, The histone methyltransferase EZH2, an oncogene common to benign and malignant parathyroid tumors. Endocr. Relat. Cancer 21(2), 231\u2013239 (2014). https:\/\/doi.org\/10.1530\/ERC-13-0497","journal-title":"Endocr. Relat. Cancer"},{"key":"3376_CR21","doi-asserted-by":"publisher","first-page":"646","DOI":"10.4161\/epi.24823","volume":"8","author":"L Sulaiman","year":"2013","unstructured":"L. Sulaiman, C.C. Juhlin, I.L. Nilsson, O. Fotouhi, C. Larsson, J. Hashemi, Global and gene-specific promoter methylation analysis in primary hyperparathyroidism. Epigenetics 8, 646\u2013655 (2013). https:\/\/doi.org\/10.4161\/epi.24823","journal-title":"Epigenetics"},{"key":"3376_CR22","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1002\/gcc.20895","volume":"50","author":"LF Starker","year":"2011","unstructured":"L.F. Starker, J. Svedlund, R. Udelsman, H. Dralle, G. Akerstr\u00f6m, G. Westin, R.P. Lifton, P. Bj\u00f6rklund, T. Carling, The DNA methylome of benign and malignant parathyroid tumors. Genes. Chromosomes Cancer 50, 735\u2013745 (2011). https:\/\/doi.org\/10.1002\/gcc.20895","journal-title":"Genes. Chromosomes Cancer"},{"key":"3376_CR23","doi-asserted-by":"publisher","first-page":"e9472","DOI":"10.1371\/journal.pone.0009472","volume":"5","author":"CC Juhlin","year":"2010","unstructured":"C.C. Juhlin, N.B. Kiss, A. Villablanca, F. Haglund, J. Nordenstr\u00f6m, A. H\u00f6\u00f6g, C. Larsson, Frequent promoter hypermethylation of the APC and RASSF1A tumour suppressors in parathyroid tumours. PLoS ONE 5, e9472 (2010). https:\/\/doi.org\/10.1371\/journal.pone.0009472","journal-title":"PLoS ONE"},{"issue":"97","key":"3376_CR24","doi-asserted-by":"publisher","first-page":"E1307","DOI":"10.1210\/jc.2011-3136","volume":"2012","author":"J Svedlund","year":"2012","unstructured":"J. Svedlund, S. Koskinen Edblom, V.E. Marquez, G. \u00c5kerstr\u00f6m, P. Bj\u00f6rklund, G. Westin, Hypermethylated in cancer 1 (HIC1), a tumor suppressor gene epigenetically deregulated in hyperparathyroid tumors by histone H3 lysine modification. J. Clin. Endocrinol. Metab. 2012(97), E1307\u2013E1315 (2012). https:\/\/doi.org\/10.1210\/jc.2011-3136","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"3376_CR25","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1677\/ERC-09-0134","volume":"17","author":"S Corbetta","year":"2010","unstructured":"S. Corbetta, V. Vaira, V. Guarnieri, A. Scillitani, C. Eller-Vainicher, S. Ferrero, L. Vicentini, I. Chiodini, M. Bisceglia, P. Beck-Peccoz, S. Bosari, A. Spada, Differential expression of microRNAs in human parathyroid carcinomas compared with normal parathyroid tissue. Endocr. Relat. Cancer 17(1), 135\u2013146 (2010). https:\/\/doi.org\/10.1677\/ERC-09-0134","journal-title":"Endocr. Relat. Cancer"},{"issue":"4","key":"3376_CR26","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1093\/jmcb\/mjy041","volume":"10","author":"S Liu","year":"2018","unstructured":"S. Liu, Z. Wang, Z. Liu, S. Shi, Z. Zhang, J. Zhang, H. Lin, miR-221\/222 activate the Wnt\/\u03b2-catenin signaling to promote triple-negative breast cancer. J. Mol. Cell. Biol. 10(4), 302\u2013315 (2018). https:\/\/doi.org\/10.1093\/jmcb\/mjy041","journal-title":"J. Mol. Cell. Biol."},{"issue":"1","key":"3376_CR27","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3390\/endocrines4010018","volume":"4","author":"F Marini","year":"2023","unstructured":"F. Marini, F. Giusti, G. Palmini, C. Aurilia, S. Donati, M.L. Brandi, Parathyroid carcinoma: update on pathogenesis and therapy. Endocrines 4(1), 205\u2013235 (2023). https:\/\/doi.org\/10.3390\/endocrines4010018","journal-title":"Endocrines"},{"issue":"5","key":"3376_CR28","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.ajhg.2016.08.018","volume":"99","author":"B Guan","year":"2016","unstructured":"B. Guan, J.M. Welch, J.C. Sapp, H. Ling, Y. Li, J.J. Johnston, E. Kebebew, L.G. Biesecker, W.F. Simonds, S.J. Marx, S.K. Agarwal, GCM2-activating mutations in familial isolated hyperparathyroidism. Am. J. Hum. Genet. 99(5), 1034\u20131044 (2016). https:\/\/doi.org\/10.1016\/j.ajhg.2016.08.018","journal-title":"Am. J. Hum. Genet."},{"issue":"3","key":"3376_CR29","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/10.1530\/EJE-21-0433","volume":"186","author":"L Canaff","year":"2022","unstructured":"L. Canaff, V. Guarnieri, Y. Kim, B.Y.L. Wong, A. Nolin-Lapalme, D.E.C. Cole, S. Minisola, C. Eller-Vainicher, F. Cetani, A. Repaci, D. Turchetti, S. Corbetta, A. Scillitani, D. Goltzman, Novel Glial Cells Missing-2 (GCM2) variants in parathyroid disorders. Eur. J. Endocrinol. 186(3), 351\u2013366 (2022). https:\/\/doi.org\/10.1016\/10.1530\/EJE-21-0433","journal-title":"Eur. J. Endocrinol."},{"issue":"10","key":"3376_CR30","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.4158\/EP-2020-0132","volume":"26","author":"A Song","year":"2020","unstructured":"A. Song, Y. Yang, Y. Wang, S. Liu, M. Nie, Y. Jiang, M. Li, W. Xia, O. Wang, X. Xing, Germline GCM2 Mutation Screening in Chinese Primary Hyperparathyroidism Patients. Endocr. Pract. 26(10), 1093\u20131104 (2020). https:\/\/doi.org\/10.4158\/EP-2020-0132","journal-title":"Endocr. Pract."},{"issue":"4","key":"3376_CR31","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1245\/s10434-010-1359-7","volume":"18","author":"R Rahbari","year":"2011","unstructured":"R. Rahbari, A.K. Holloway, M. He, E. Khanafshar, O.H. Clark, E. Kebebew, Identification of differentially expressed microRNA in parathyroid tumors. Ann. Surg. Oncol. 18(4), 1158\u20131165 (2011). https:\/\/doi.org\/10.1245\/s10434-010-1359-7","journal-title":"Ann. Surg. Oncol."},{"issue":"4","key":"3376_CR32","doi-asserted-by":"publisher","first-page":"e00284","DOI":"10.1002\/edm2.284","volume":"4","author":"J Krupinova","year":"2021","unstructured":"J. Krupinova, N. Mokrysheva, V. Petrov, E. Pigarova, A. Eremkina, E. Dobreva, A. Ajnetdinova, G. Melnichenko, A. Tiulpakov, Serum circulating miRNA-342-3p as a potential diagnostic biomarker in parathyroid carcinomas: a pilot study. Endocrinol. Diabetes Metab. 4(4), e00284 (2021). https:\/\/doi.org\/10.1002\/edm2.284","journal-title":"Endocrinol. Diabetes Metab."},{"issue":"4","key":"3376_CR33","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s40618-014-0234-y","volume":"38","author":"C Verdelli","year":"2015","unstructured":"C. Verdelli, I. Forno, V. Vaira, S. Corbetta, MicroRNA deregulation in parathyroid tumours suggests an embryonic signature. J. Endocrinol. Investig. 38(4), 383\u2013388 (2015). https:\/\/doi.org\/10.1007\/s40618-014-0234-y","journal-title":"J. Endocrinol. Investig."},{"issue":"12","key":"3376_CR34","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1002\/jbmr.4154","volume":"35","author":"A Morotti","year":"2020","unstructured":"A. Morotti, I. Forno, C. Verdelli, V. Guarnieri, F. Cetani, A. Terrasi, R. Silipigni, S. Guerneri, V. Andr\u00e8, A. Scillitani, L. Vicentini, S. Ferrero, S. Corbetta, V. Vaira, The oncosuppressors MEN1 and CDC73 are involved in lncRNA deregulation in human parathyroid tumors. J. Bone Miner. Res 35(12), 2423\u20132431 (2020). https:\/\/doi.org\/10.1002\/jbmr.4154","journal-title":"J. Bone Miner. Res"},{"key":"3376_CR35","doi-asserted-by":"publisher","first-page":"869006","DOI":"10.3389\/fendo.2022.869006","volume":"13","author":"A Morotti","year":"2022","unstructured":"A. Morotti, F. Cetani, G. Passoni, S. Borsari, E. Pardi, V. Guarnieri, C. Verdelli, G.S. Tavanti, L. Valenti, C. Bianco, S. Ferrero, S. Corbetta, V. Vaira, The long non-coding BC200 is a novel circulating biomarker of parathyroid carcinoma. Front. Endocrinol. 13, 869006 (2022). https:\/\/doi.org\/10.3389\/fendo.2022.869006","journal-title":"Front. Endocrinol."},{"issue":"12","key":"3376_CR36","doi-asserted-by":"publisher","first-page":"3990","DOI":"10.1245\/s10434-015-4672-3","volume":"22","author":"EA Asare","year":"2015","unstructured":"E.A. Asare, C. Sturgeon, D.J. Winchester, L. Liu, B. Palis, N.D. Perrier, D.B. Evans, D.P. Winchester, T.S. Wang, Parathyroid carcinoma: an update on treatment outcomes and prognostic factors from the National Cancer Data Base (NCDB). Ann. Surg. Oncol. 22(12), 3990\u20133995 (2015). https:\/\/doi.org\/10.1245\/s10434-015-4672-3","journal-title":"Ann. Surg. Oncol."},{"key":"3376_CR37","doi-asserted-by":"publisher","unstructured":"F. Cetani, E. Pardi, C. Marcocci, Parathyroid carcinoma. in Parathyroid Disorders. Focusing on Unmet Needs ed. by M.L. Brandi Front. Horm. Res., Kager. 51, pp. 63\u201376 (2019). https:\/\/doi.org\/10.1159\/isbn.978-3-318-06409-4","DOI":"10.1159\/isbn.978-3-318-06409-4"},{"issue":"4","key":"3376_CR38","doi-asserted-by":"publisher","first-page":"e10114","DOI":"10.1002\/jbm4.10114","volume":"3","author":"S Storvall","year":"2018","unstructured":"S. Storvall, E. Ryh\u00e4nen, F.V. Bensch, I. Heiskanen, S. Kyt\u00f6l\u00e4, T. Ebeling, S. M\u00e4kel\u00e4, C. Schalin-J\u00e4ntti, Recurrent metastasized parathyroid carcinoma-long-term remission after combined treatments with surgery, radiotherapy, cinacalcet, zoledronic acid, and temozolomide. JBMR 3(4), e10114 (2018). https:\/\/doi.org\/10.1002\/jbm4.10114","journal-title":"JBMR"},{"issue":"11","key":"3376_CR39","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1210\/js.2019-00175","volume":"3","author":"S Storvall","year":"2019","unstructured":"S. Storvall, E. Ryh\u00e4nen, I. Heiskanen, T. Vesterinen, F.V. Bensch, J. Schildt, S. Kyt\u00f6l\u00e4, A. Karhu, J. Arola, C. Schalin-J\u00e4ntti, MGMT promoter methylation and parathyroid carcinoma. J. Endocr. Soc. 3(11), 2114\u20132122 (2019). https:\/\/doi.org\/10.1210\/js.2019-00175","journal-title":"J. Endocr. Soc."},{"issue":"10","key":"3376_CR40","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.1210\/jc.2007-0585","volume":"92","author":"SJ Silverberg","year":"2007","unstructured":"S.J. Silverberg, M.R. Rubin, C. Faiman, M. Peacock, D.M. Shoback, R.C. Smallridge, L.E. Schwanauer, K.A. Olson, P. Klassen, J.P. Bilezikian, Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J. Clin. Endocrinol. Metab. 92(10), 3803\u20133808 (2007). https:\/\/doi.org\/10.1210\/jc.2007-0585","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"3376_CR41","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1007\/s00774-016-0797-0","volume":"35","author":"Y Takeuchi","year":"2017","unstructured":"Y. Takeuchi, S. Takahashi, D. Miura, M. Katagiri, N. Nakashima, H. Ohishi, R. Shimazaki, Y. Tominaga, Cinacalcet hydrochloride relieves hypercalcemia in Japanese patients with parathyroid cancer and intractable primary hyperparathyroidism. J. Bone Miner. Metab. 35(6), 616\u2013622 (2017). https:\/\/doi.org\/10.1007\/s00774-016-0797-0","journal-title":"J. Bone Miner. Metab."},{"issue":"3","key":"3376_CR42","doi-asserted-by":"publisher","first-page":"755","DOI":"10.3390\/ijms20030755","volume":"20","author":"T Tian","year":"2019","unstructured":"T. Tian, X. Li, J. Zhang, mTOR signaling in cancer and mTOR inhibitors in solid tumor targeting therapy. Int. J. Mol. Sci. 20(3), 755 (2019). https:\/\/doi.org\/10.3390\/ijms20030755","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"3376_CR43","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1530\/eje.1.02168","volume":"154","author":"AC Lazaris","year":"2006","unstructured":"A.C. Lazaris, S. Tseleni-Balafouta, T. Papathomas, T. Brousalis, G. Thomopoulou, G. Agrogiannis, E.S. Patsouris, Immunohistochemical investigation of angiogenic factors in parathyroid proliferative lesions. Eur. J. Endocrinol. 154(6), 827\u2013833 (2006). https:\/\/doi.org\/10.1530\/eje.1.02168","journal-title":"Eur. J. Endocrinol."},{"key":"3376_CR44","doi-asserted-by":"publisher","first-page":"664847","DOI":"10.3389\/fimmu.2021.664847","volume":"12","author":"XJ Chen","year":"2021","unstructured":"X.J. Chen, A.Q. Ren, L. Zheng, E.D. Zheng, Predictive value of KDM5C alterations for immune checkpoint inhibitors treatment outcomes in patients with cancer. Front. Immunol. 12, 664847 (2021). https:\/\/doi.org\/10.3389\/fimmu.2021.664847","journal-title":"Front. Immunol."},{"key":"3376_CR45","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1530\/EDM-16-0113","volume":"2017","author":"L Rozhinskaya","year":"2017","unstructured":"L. Rozhinskaya, E. Pigarova, E. Sabanova, E. Mamedova, I. Voronkova, J. Krupinova, L. Dzeranova, A. Tiulpakov, V. Gorbunova, N. Orel, A. Zalian, G. Melnichenko, I. Dedov, Diagnosis and treatment challenges of parathyroid carcinoma in a 27-year-old woman with multiple lung metastases. Endocrinol. Diabetes Metab. Case Rep. 2017, 16\u20130113 (2017). https:\/\/doi.org\/10.1530\/EDM-16-0113","journal-title":"Endocrinol. Diabetes Metab. Case Rep."},{"issue":"22","key":"3376_CR46","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.2169\/internalmedicine.9261-21","volume":"61","author":"H Makino","year":"2022","unstructured":"H. Makino, M. Notsu, I. Asayama, H. Otani, M. Morita, M. Yamamoto, M. Yamauchi, M. Nakao, H. Miyake, A. Araki, S. Uchino, K. Kanasaki, Successful control of hypercalcemia with sorafenib, evocalcet, and denosumab combination therapy for recurrent parathyroid carcinoma. Intern. Med. 61(22), 3383\u20133390 (2022). https:\/\/doi.org\/10.2169\/internalmedicine.9261-21","journal-title":"Intern. Med."},{"key":"3376_CR47","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3389\/fendo.2018.00641","volume":"9","author":"N Alharbi","year":"2018","unstructured":"N. Alharbi, S.L. Asa, M. Szybowska, R.H. Kim, S. Ezzat, Intrathyroidal parathyroid carcinoma: an atypical thyroid lesion. Front. Endocrinol. 9, 641 (2018). https:\/\/doi.org\/10.3389\/fendo.2018.00641","journal-title":"Front. Endocrinol."},{"issue":"1","key":"3376_CR48","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1210\/jc.2012-2426","volume":"98","author":"K Vandyke","year":"2013","unstructured":"K. Vandyke, S. Fitter, J. Drew, S. Fukumoto, C.G. Schultz, N.A. Sims, D.T. Yeung, T.P. Hughes, A.C. Zannettino, Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: evidence for site-specific skeletal effects. J. Clin. Endocrinol. Metab. 98(1), 67\u201376 (2013). https:\/\/doi.org\/10.1210\/jc.2012-2426","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-023-03376-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-023-03376-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-023-03376-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T06:14:30Z","timestamp":1691129670000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-023-03376-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,9]]},"references-count":48,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["3376"],"URL":"https:\/\/doi.org\/10.1007\/s12020-023-03376-w","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,9]]},"assertion":[{"value":"17 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}